The Promus Element Plus, built on the Promus Element stent design, features a modified catheter delivery system, according to a press release.
"We are pleased to introduce the Promus Element Plus Stent System to physicians and patients in Canada," interventional cardiology president Kevin Balligner said in prepared remarks.
"It is the latest example of Boston Scientific’s commitment to market leadership and continued innovation in drug-eluting stents," he added.
BSX shares were up 0.7% to $6.09 as of about 2:15 p.m. today.
The private-label deal ended in Europe in 2009, but a similar arrangement in the U.S. is slated to go until mid-2012. Dwindling royalty payments from the Promus stents were noted in Abbott’s sliding Q1 2012 vascular sales.